Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer

Open-label, Dose-escalation, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre Efficacy of BVAC-C in Patients With Multiple Metastatic Progressive or Recurrent HPV Type 16 or 18 Positive Cervical Cancer After Failure to Standard Care

Sponsors

Lead Sponsor: Cellid Co., Ltd.

Source Cellid Co., Ltd.
Brief Summary

BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts. Phase I is for safety evaluation, and Phase IIa is for efficacy assessment.

Detailed Description

BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts(Phase I, Phase II). Phase I study is Open-label, dose-escalation, multiple dosing study to evaluate the safety, tolerability, immune response and preliminary efficacy of BVAC-C in patients with multiple metastatic progressive or recurrent HPV type 16 or 18 positive cervical cancer after failure to standard care. 9~18 patients will be enrolled In Phase IIa study, which Open-label, sequential assignment multiple dosing study, efficacy, immune response and safety will be evaluated. Total 21 patients will be enrolled in 3 groups.

Overall Status Active, not recruiting
Start Date 2016-10-01
Completion Date 2021-12-01
Primary Completion Date 2021-04-01
Phase Phase 1/Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Evaluate DLT with Clinical laboratory tests [Safety] 12th week from first injection (End of trial)
Incidence of Serious Adverse Events assessed with CTCAE [Safety] 12th week from first injection (End of trial)
Secondary Outcome
Measure Time Frame
Clinical laboratory tests Screening visit and every 2 weeks from first injection (up to 12th week)
12-lead ECG Screening visit and Termination visit (12th week from first injection)
Vital signs Every 2 weeks from first injection (up to 12th week)
Physical examination Screening, 6th week from first injection, 10th week from first injection and Termination visit (12th week from first injection)
Enrollment 32
Condition
Intervention

Intervention Type: Drug

Intervention Name: BVAC-C

Description: Autologous B cells and monocytes transfected with E6E7 gene of HPV

Intervention Type: Drug

Intervention Name: Topotecan

Arm Group Label: BVAC-C + Topo Combi

Eligibility

Criteria:

Inclusion Criteria: - Patients with multiple metastatic progressive or recurrent HPV type 16 or 18 positive cervical cancer - Patients has received 1 or more platinum based doublet chemotherapy as prior therapy for progressive or recurrent tumor lesion (prior therapy does not include platinum chemotherapy given with radiation therapy for 1st line treatment before progression or recurrence) - Patients with at least 1 measurable lesion according to RECIST - Female patients between ages of 20 to 70 - Patients with ECOG performance status between 0 to 2 - Patients meets the blood test standards in the screening test - ANC≥1500/μL - LLN ≤ALC ≤ULN - Platelets≥100,000/μL - Hemoglobin> 9g/dL - Patients meets the blood chemistry test standards in the screening test - Serum creatinine ≤ 2.0 mg/dL - Calculated creatinine clearance ≥ 50 mL/min - Serum bilirubin ≤1.5 x ULN - ALT and AST ≤2.5 × ULN (≤ 5 x ULN in patients with liver metastases) - Patients who has agreed to a medically accepted contraceptive in this clinical trial - Patients at least three months or more of survival can be expected - Patients decided to participate in this clinical trial and signed written informed consent Exclusion Criteria: - Patients histopathology is a neuroendocrine or small cell carcinoma - Patients with a history of brain metastasis or signs of brain metastasis - Patients tested positive in serological tests for hepatitis C virus or hepatitis B virus surface antigen, (HBsAg) or human immunodeficiency virus (HIV) - Patients with a history of HIV infection - Patients showing abnormal electrocardiogram , including arrhythmia - Patients have been administered the drug for other clinical trials within 4weeks before the screening visit - Patients have been administered any vaccines within 4weeks before the screening visit (eg. hepatitis A, hepatitis B, influenza, Td, etc. ) - Patients have been administered the blood products within 3 months before the screening visit - Patients have received chemotherapy or radiation therapy within 4weeks before the 1st administration of investigational drug (BVAC-C) - Patients treated with immunosuppressant or immunomodulatory agents within 6 months before the screening visit - Patients who have participated in the clinical trial of a therapeutic vaccine or immune therapy within 1 year before the screening visit - Patients with a history of serious allergic disease or serious side effects of the drug - Patients who is pregnant or breast-feeding - Patients researchers has determined that participation in the clinical trial is inappropriate - Patients suspected to have other primary cancer

Gender:

Female

Minimum Age:

20 Years

Maximum Age:

N/A

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
C Y Kang, PH.D Study Chair Seoul National University
Location
Facility: Samsung Medical Center
Location Countries

Korea, Republic of

Verification Date

2020-12-01

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 3
Arm Group

Label: BVAC-C mono(High dose)

Type: Experimental

Description: BVAC-C IV injection at 0, 4, 8th weeks.(HIgh dose)

Label: BVAC-C mono(Intermediate dose)

Type: Experimental

Description: BVAC-C IV injection at 0, 4, 8, 12th weeks.(Half dose)

Label: BVAC-C + Topo Combi

Type: Experimental

Description: BVAC-C IV injection at 0,4,8,12th weeks.(Half dose) Topotecan IV injection at 2, 6, 10, 14th weeks

Patient Data Undecided
Study Design Info

Allocation: Non-Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News